Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 4/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.40 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.40 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6501299 | 0.79 | CA4 (0.34) | — | |
| SCHEMBL31032787 | 0.74 | CHRNB2 (0.50) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL3984987 | 0.73 | CHRNB2 (0.53) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Hydrochloric Acid SCHEMBL3296537 | 0.71 | CHRNB2 (0.51) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL6503405 | 0.69 | CYP1A2 (0.44) | — | |
| SCHEMBL4705276 | 0.67 | CHRNB2 (0.43) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL6490088 | 0.66 | PSMB1 (0.42) | LMNA | |
| SCHEMBL10597215 | 0.65 | — | — | |
| SCHEMBL6498977 | 0.65 | ELANE (0.49) | LMNA | |
| SCHEMBL16590522 | 0.65 | ALDH1A1 (0.40) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6579328-B2 | Preparation from a sterically hindered nitroxy compound and a diazonium salt of an aromatic amine in the presence of a transition metal catalyst | CIBA SPECIALTY CHEMICALS CORPORATION | 2003-06-17 | — | — | US | claimed |
| EP-1278733-A1 | PROCESS FOR THE PREPARATION OF STERICALLY HINDERED ARYLOXYAMINES | Ciba SC Holding AG (CH) | 2003-01-29 | — | — | EP | claimed |
| US-20020007585-A1 | Transition-metal-catalyzed process for the preparation of sterically hindered N-substituted aryloxyamines | CIBA SPECIALTY CHEMICALS CORP. | 2002-01-24 | — | — | US | claimed |
| WO-2001083455-A1 | PROCESS FOR THE PREPARATION OF STERICALLY HINDERED ARYLOXYAMINES | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2001-11-08 | — | — | WO | claimed |
| US-6841668-B2 | Polyoxometalate catalysts for the preparation of sterically hindered N-substituted aryloxyamines | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 2005-01-11 | — | — | US | disclosed |
| US-20030208071-A1 | Polyoxometalate catalysts for the preparation of sterically hindered N-substituted aryloxyamines | CIBA SPECIALTY CHEMICALS CORP. | 2003-11-06 | — | — | US | disclosed |
| US-6579328-B2 | Preparation from a sterically hindered nitroxy compound and a diazonium salt of an aromatic amine in the presence of a transition metal catalyst | CIBA SPECIALTY CHEMICALS CORPORATION | 2003-06-17 | — | — | US | disclosed |
| EP-1278733-A1 | PROCESS FOR THE PREPARATION OF STERICALLY HINDERED ARYLOXYAMINES | Ciba SC Holding AG (CH) | 2003-01-29 | — | — | EP | disclosed |
| US-20020007585-A1 | Transition-metal-catalyzed process for the preparation of sterically hindered N-substituted aryloxyamines | CIBA SPECIALTY CHEMICALS CORP. | 2002-01-24 | — | — | US | disclosed |
| WO-2001083455-A1 | PROCESS FOR THE PREPARATION OF STERICALLY HINDERED ARYLOXYAMINES | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2001-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030208071-A1 | Polyoxometalate catalysts for the preparation of sterically hindered N-substituted aryloxyamines | KMO, PPOX, TAOK1 | CHRNB2 2678/4885CHRNA4 2864/4885CHRNB4 2624/4885 |
| US-20020007585-A1 | Transition-metal-catalyzed process for the preparation of sterically hindered N-substituted aryloxyamines | SOD1, NNMT, TYR | CHRNB2 1727/4885CHRNA4 1115/4885CHRNB4 1534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.